GlassScriptPhysician profile
Sergio R Vaisman
NPI 1063487783
$415.14
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $251 · 2021: $67.96 · 2022: $95.96.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $67.55 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $47.22 | 2022 | |
| Lilly USA, LLC | $39.71 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $37.42 | 2021 | |
| Alexion Pharmaceuticals, INC. | $24.75 | 2019 | |
| Shionogi INC | $22.87 | 2019 | |
| Romark Laboratories, Lc | $22.15 | 2019 | |
| Medtronic, INC. | $21.54 | 2022 | |
| Ucb, INC. | $20.34 | 2019 | |
| Baxter Healthcare | $19.86 | 2019 | |
| Opko Pharmaceuticals, LLC | $19.10 | 2019 | |
| Mallinckrodt Enterprises LLC | $17.50 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $15.56 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $14.48 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.60 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $11.49 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sergio Vaisman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.